Although much progress has been made in the understanding of the ontogeny and function of dendritic cells (DCs), the transcriptional regulation of the lineage commitment and functional specialization of DCs in vivo remains poorly understood. We made a comprehensive comparative analysis of CD8 + , CD103 + , CD11b + and plasmacytoid DC subsets, as well as macrophage DC precursors and common DC precursors, across the entire immune system. Here we characterized candidate transcriptional activators involved in the commitment of myeloid progenitor cells to the DC lineage and predicted regulators of DC functional diversity in tissues. We identified a molecular signature that distinguished tissue DCs from macrophages. We also identified a transcriptional program expressed specifically during the steady-state migration of tissue DCs to the draining lymph nodes that may control tolerance to self tissue antigens. 
r e s o u r c e
The Immunological Genome (ImmGen) Project is a consortium of immunologists and computational biologists from many institutions who have united to create an exhaustive database of gene-expression and regulatory-gene networks across the entire mouse hematopoietic lineage with the same rigorously controlled data-generation pipeline. With this extensive database, we sought to define the transcriptional profile and regulatory networks that control the homeostasis and function of the lineage development of dendritic cells (DCs). Discovered only 50 years ago, DCs are the most recent addition to the hematopoietic cell lineage 1 . DCs represent a small population of hematopoietic cells that share properties with tissue macrophages, including their localization in most tissues and their ability to sample extracellular antigens, sense environmental injuries and contribute to the induction of tissue immune responses 1 . However, in contrast to macrophages, whose main role is to scavenge damaged cells or pathogenic microbes and promote tissue repair, the main function of DCs is to initiate antigen-specific adaptive immune responses to foreign antigens that breach the tissues 2 , as well as to maintain tolerance to self antigens 3 . The unique role of DCs in adaptive immunity relies on their ability to process and present self and foreign antigens in the form of complexes of peptide and major histocompatibility complex (MHC) class I and MHC class II on the cell surface 4, 5 , together with their superior ability to migrate to the tissue-draining lymph nodes 6 and localize together with T lymphocytes and B lymphocytes 7 .
This makes DCs uniquely poised to control the induction of an antigen-specific immune response. However, controversies still exist about the overall distinction between DCs and macrophages because of their partially overlapping phenotypes and functions and, consequently, the exact contribution of macrophages and DCs to tissue immune responses is still debated 8, 9 .
DCs consist of distinct subsets with different abilities to process antigens, respond to environmental stimuli and engage distinct effector lymphocytes 10 . Classical DCs (cDCs) form the predominant DC subset and are further subcategorized as lymphoid tissue-resident CD8 + cDCs and CD8 -cDCs 11 . Lymphoid tissue-resident cDC subsets are functionally specialized; CD8 + cDCs excel in the cross-presentation of cell-associated antigens to CD8 + T cells, whereas CD8 -cDCs are the most potent at stimulating CD4 + T cells. The second main subset of DCs are the plasmacytoid DCs (pDCs). The pDCs are uniquely able to produce large amounts of the antiviral cytokine interferon-α and initiate T cell immunity to viral antigens 12 . Nonlymphoid-tissue DCs also include two cDC subsets: the CD103 + cDCs and the CD11b + cDCs 13 . Similar to lymphoid-tissue CD8 + cDCs, nonlymphoid-tissue CD103 + cDCs are efficient cross-presenters of cell-associated antigens and are the most potent at stimulating CD8 + T cells 10 but may also facilitate the induction of regulatory T cells in the intestine 14 .
The successive steps that lead to commitment to the DC lineage in the bone marrow are starting to be characterized. A myeloid r e s o u r c e precursor cell called the 'macrophage and DC precursor' (MDP) 15 has been identified and has been shown to give rise to monocytes and to the common DC precursor (CDP) 16 . CDPs are clonogenic precursor cells that have lost the potential to differentiate into monocytes or macrophages and give rise exclusively to pDCs and cDCs 17, 18 . CDPs also produce pre-cDCs, which are circulating cDC-restricted progenitor cells that have lost the potential to differentiate into pDCs 16 and home to tissues to differentiate locally into lymphoid tissue-resident CD8 + or CD8 -cDCs 16 and nonlymphoid tissue-resident cDCs 19 . Although much progress has been made in understanding the ontogeny and function of DCs, the transcriptional regulation of commitment to the DC lineage and the diversification and functional specialization of DCs in vivo, as well as the relationship between lymphoid-tissue DCs and nonlymphoid-tissue DCs, remain poorly understood. These questions remain unanswered in part because of the limited data available for comprehensive, comparative analysis both vertically and horizontally across the immune system.
Here we delineate the transcriptional network of DC progenitor cells, lymphoid-tissue and nonlymphoid-tissue DCs, as well as nonlymphoid-tissue DCs in a migratory state. The results of our study help characterize a DC-specific signature that distinguishes cDCs from macrophages in tissues. Our study identifies the lineage relationship between various tissue DC subsets as well as the predicted regulators of tissue DC diversity. Our results also identify a signature of genes expressed by all nonlymphoid-tissue cDCs that have migrated to the draining lymph nodes, regardless of their tissue or lineage origin.
RESULTS

Transcriptional characterization of the DC lineage
We characterized 26 distinct DC populations isolated from primary lymphoid tissues, secondary lymphoid tissues and nonlymphoid tissues on the basis of expression of markers on the cell surface thought to represent discrete DC subsets with specialized immunological function in vivo 13 (Table 1) . We sorted each subset to high purity according to the standard operating protocol of the ImmGen Project. We isolated CD8 + and CD8 -cDCs and pDCs from the spleen, thymus and lymph nodes; purified CD103 + cDCs and CD11b + cDCs from the lung, liver, small intestine and kidney; and isolated epidermal Langerhans cells (LCs) from the epidermis. We isolated tissuemigratory CD103 + DCs and CD11b + DCs from tissue-draining lymph nodes. We purified granulocyte-macrophage precursors (GMPs), MDPs and CDPs from the bone marrow and isolated circulating monocytes from the blood. We double-sorted cell populations to a purity of over 99% on the basis of the appropriate cell surface markers ( Table 1) . We did the final sorting by flow cytometry (10,000-30,000 cells) directly in TRIzol, froze the samples after 2 min and sent them to the core team of the ImmGen Project in Boston, Massachusetts. RNA was prepared from the TRIzol lysate and hybridized to microarrays as described 21 . Expression profiling data were generated on Affymetrix ST1.0 microarrays according to the ImmGen Project pipeline, with data generation and quality control as described before 21 . The purified DC subsets were isolated from laboratories in New York, New York, and Boston, Massachusetts. One population of spleen DCs (population 1, sorted in New York) was sorted on the basis of expression of MHC class II and CD11c and lack of expression of F4/80 or B220 and was found to be identical to spleen DCs (population 2, sorted in Boston) purified mainly on the basis of CD11c expression. For analysis of whether site or batch effects may have confounded the signals, CD8 + and CD8 -spleen cDCs were sorted independently at the two different locations (New York and Boston). The data showed excellent correlation in each subset, with little evidence of lab-specific influences, for the differences between CD8 -and CD8 + cDC subsets (Supplementary Fig. 1 ).
Transcriptional control of commitment to the DC lineage
The commitment of cells of the myeloid lineage to the mononuclear phagocyte lineage is determined at the stage of the MDP, at which point erythroid, megakaryocyte, lymphoid and granulocyte fates have been precluded 15, 16, 22 . DC commitment occurs during the transition from MDP to CDP, with the loss of monocyte potential 16 , whereas cDC commitment occurs at the pre-cDC stage, with the loss of pDC potential 17, 18 . We probed the pattern of regulator expression along the myeloid-DC lineage tree to search for transcriptional activators and repressors that correlated with each differentiation step and thereby identified groups of genes encoding regulators that were induced at different stages during DC differentiation. The first group was upregulated specifically during the differentiation of GMPs into MDPs (expression 1.5-fold or more higher in MDPs than in GMPs; Fig. 1a, i) , which would potentially influence the global development of DCs and macrophages. This group included Sox4 and Taf4b, which encode transcription factors known to have a role in cell fate and the initiation of transcription, respectively. The second group was upregulated during the transition from MDP or GMP to CDP (expression 1.5-fold or more higher in CDPs than in MDPs or GMPs) but not during the differentiation of MDPs into circulating monocytes (Fig. 1a , ii) and encoded molecules that probably control CDP-versus-monocyte fate. This group included genes encoding molecules known to regulate pDC development, such as Irf8, Bcl11a and Runx2, as well as low expression of Zbtb46 (which encodes zinc-finger transcription factor Zbtb46). A third group was downregulated (67% lower expression; Fig. 1a , iii) during the transition from GMP to MDP and included Tgif1 (a homeobox gene induced by transforming growth factor-β (TGF-β)), Tcfec (which encodes a transcription factor) and Trim13 (which encodes an E3 ubiquitin ligase). To search for regulators that might contribute to the pDC-versus-cDC fate of CDPs, we examined the expression of candidate genes encoding regulators during the differentiation of CDPs into pDCs, lymphoid-tissue CD8 + cDCs or lymphoid-tissue CD8 -cDCs (Supplementary Fig. 2 ). The differentiation of CDPs into pDCs was associated with the downregulation of Id2, Zbtb46 and Cited2 (which encodes a regulator of TGF-β), whereas the differentiation of CDPs into cDCs was associated with the downregulation of Irf8, Tcf4 and Runx2 and upregulation of Batf3, Bcl6 and Ciita (which all encode transcription factors). We also identified genes encoding transcription factors that were upregulated 1.5-fold or more in CD8 + cDCs relative to their expression in CD8 -cDCs (and vice versa). These included expected genes such as Irf8, which encodes the CD8 + cell-and CD103 + cell-specific transcription factor IRF8 (refs. 19-23) , as well as Pbx1, which encodes a Hox transcription factor shown to function during definitive hematopoiesis in fetal liver 24 .
Several transcription factors identified in our analysis have been shown to control DC development. For example, the differentiation of pDCs and cDCs is dependent on the zinc-finger protein Ikaros 25 , the cytokine receptor Flt3 and its ligand Flt3L 26 (and Flt3 expression is partly controlled by the transcription factor PU.1 (encoded by Sfpi1) 27 ), and the transcription factor STAT3, which is activated by Flt3 signaling and mediates Flt3L-dependent DC differentiation 28 . Factors that regulate DC diversification are also starting to be identified. The transcription factors E2-2 (encoded by Tcf4), Spi-B and npg r e s o u r c e IRF8 have been shown to control pDC differentiation 29 , whereas Bcl-6 controls the development of cDCs but not of pDCs 30 in the spleen. The transcription factors BATF3, IRF8, Id2 and mTOR control the development of CD8 + cDCs and CD103 + cDCs, whereas the differentiation of CD8 -cDCs is controlled by the transcription factors IRF2, IRF4 (ref. 8) and Notch2 (ref. 20) , a factor that also controls the differentiation of intestinal CD103 + CD11b + cDCs 20 . Consistent with our finding that Zbtb46 expression was associated with the commitment of CDPs to the cDC lineage, two published studies have shown that Zbtb46 expression is restricted to cDC-committed precursor cells and tissue cDCs and that Zbtb46 can serve as a useful marker for distinguishing cDCs from other tissue phagocytes 31, 32 . Together these results provided a map of known regulators and also previously unknown potential regulators that accompanied key checkpoints in the generation of DCs and helped to identify the molecular cues that control differentiation into the monocyte or DC lineage as well as DC diversification in vivo.
Identification of a cDC core gene signature One of the main challenges in understanding the exact contribution of cDCs versus macrophages in tissue immunity has been the lack of specific phenotypic markers for defining tissue cDCs. We first ascertained whether cDCs and macrophages sorted on the basis of published markers clustered as one population or as separate populations by principalcomponent analysis (PCA) of the 15% of genes with the most variable expression by various steady-state leukocytes isolated from the same organ (Supplementary Fig. 1d ). These results showed that macrophages and cDCs formed distinct populations at the transcriptome level.
We then sought to determine whether cDCs expressed a set of genes present in all cDC subsets but absent from macrophages. As nonlymphoid-tissue CD11b + cDCs probably form a heterogeneous population 8, 9 , we excluded those cells from our comparative analysis and investigated whether lymphoid-tissue CD8 + cDCs and CD8 -cDCs and nonlymphoid-tissue CD103 + cDCs shared specific cDC transcripts absent from four prototypical macrophage populations Expression of cell-surface markers by DCs purified by flow cytometry from the bone marrow (precursor cells) or tissues (differentiated cells) according to standard operation procedures of the ImmGen Project. The spleen pDCs include a CD8 + subset and a CD8 − subset. CSF1R, colony-stimulating factor 1 receptor; Lang, langerin; BM, bone marrow; NY and MA, DCs isolated from laboratories in New York, New York, and Boston, Massachusetts, respectively. Data are representative of at least three experiments.
npg r e s o u r c e profiled by the ImmGen Project (Online Methods). We found 24 genes expressed in cDCs (with a change in expression of twoabsent from red-pulp macrophages, lung alveolar macrophages, peritoneal macrophages and microglia (Fig. 2b) . Together these results identified a core DC signature that helped distinguish tissue DCs from macrophages in tissues.
Unique gene signatures of distinct tissue DC clusters DC subsets are classified on the basis of distinct cell-surface markers, and different subsets exist in lymphoid and nonlymphoid tissues.
To understand the relationships among these various DCs populations, Supplementary Fig. 2 ); results were log-transformed, normalized (to the mean expression of zero across samples) and centered, and populations and genes were clustered by pairwise centroid linkage with the Pearson correlation. Data are representative of at least three experiments with three or more replicates (unless noted otherwise in Table 1 ).
fold or more between cDC and macrophages, and a false-discovery rate (FDR) of 0.05 or less (t-test)) and absent from macrophages, as determined by expression values below the 'QC95' value (the value at which the gene has a 95% chance of being expressed; Fig. 2a and Table 2 ). This group formed the 'core cDC signature' and included the gene (Ccr7) that encodes the chemokine receptor CCR7, which has been shown to control the migration of cDCs to the draining lymph nodes 33 ; Zbtb46, which was first upregulated at the CDP stage (Fig. 1a) ; and Flt3, which encodes the cytokine receptor known to control the differentiation and homeostasis of DCs 22, 34 . Although many of the genes that showed enrichment in cDCs and were absent from macrophages were also present in other hematopoietic cell populations, Zbtb46, Flt3, Pvrl1 and Anpep (which encodes the aminopeptidase CD13) showed substantial upregulation in cDCs relative to their expression in all other hematopoietic cell subsets ( Supplementary Fig. 3 and Supplementary Table 1) . Notably, many genes encoded products with no identified role in cDC biology, such as Kit, which encodes c-Kit, the receptor for stem cell factor (Kit ligand), known for its role in hematopoiesis as well as mast-cell differentiation 35 , and Btla, which encodes CD272, a member of the immunoglobulin superfamily that attenuates signaling mediated by B cell and T cell antigen receptors 36 . Btla was specifically upregulated in CD8 + cDC and CD103 + cDC populations relative to its expression in CD8 -cDCs (Fig. 2, Supplementary Fig. 3 and Supplementary Table 1 ). Several genes were upregulated twofold or more (FDR ≤0.05 (t-test)) in cDCs relative to their expression in macrophages, including many genes encoding MHC class II molecules, as well as Dpp4 (Fig. 2a and Table 3 ), which encodes the dipeptidyl peptidase CD26, whose role in DC function remains unclear. By flow cytometry, we confirmed that Flt3, c-Kit, the inhibitory receptor CD272 (BTLA) and CD26 were expressed as proteins on spleen CD8 + cDCs and spleen CD8 -cDCs, as well as nonlymphoid-tissue CD103 + cDCs, and were npg r e s o u r c e we did PCA of the 15% of genes with the most variable expression in populations of lymphoid-tissue pDCs (from the spleen, skindraining lymph nodes and mesenteric lymph nodes), lymphoid-tissue cDCs (lymph node, spleen and thymus CD8 + cDCs; lymph node and spleen CD8 -CD4 + cDCs; and spleen CD8 -CD4 -CD11b + cDCs) and nonlymphoid-tissue CD103 + cDCs (from the lung, liver and small intestine). The main principal components identified three distinct DC clusters: one cluster was formed by lymphoid-tissue CD8 + cDCs and nonlymphoid-tissue CD103 + cDCs, a second cluster was formed by lymphoid-tissue CD8 -cDCs and a third cluster was formed by pDCs (Fig. 3a) . We used these clusters to define specific gene-expression signatures. The pDC cluster expressed 93 genes absent from other cDCs, whereas the two cDC clusters expressed 125 genes absent from pDCs, including Zbtb46, Pvrl1 and Anpep (Fig. 3b, Supplementary  Fig. 4 and Supplementary Table 1 ). Further analysis of the two cDC subsets showed 28 genes shared by CD8 + cDCs and CD103 + cDCs and absent from other cDCs (Fig. 3b, Supplementary Figs. 3 and 4 and Supplementary Table 1) . Genes specific to CD8 + cDCs and CD103 + cDCs included Tlr3 (which encodes Toll-like receptor 3 (TLR3)) and Xcr1 (which encodes the chemokine receptor CCXCR1). In agreement with their unique expression of TLR3, CD8 + cDCs and CD103 + CD11b -cDCs share a superior ability to respond to TLR3 ligands [37] [38] [39] [40] . In addition, published data have shown that CD8 + DCs are also the only lymphoid-tissue DC subset that produces interferon-λ in response to the TLR3 ligand poly(I:C) 41 , and we have obtained similar results for lung CD103 + CD11b -DCs (J.H. and M.M., data not shown). Notably, Xcr1 (encoding CCXCR1, which controls the differentiation of CD8 + T effector cells in mice and humans 42, 43 ) was expressed only in CD8 + cDCs and CD103 + cDCs across the entire hematopoietic cell lineage ( Supplementary Fig. 4c 
Ass1 Events (% of max) Tables 2 and 3 ; presented as in Fig. 1b) . Yellow highlighting indicates transcripts expressed in cDCs and absent from macrophages according to the QC95 value; these form the core cDC signature. SDLN, skin-draining lymph node; MLN, mesenteric lymph node; SI, small intestine; MF, macrophage; (1) Supplementary Fig. 4 and Supplementary Fig. 4 and Supplementary Table 1 ). Dscam has enormous molecular diversity and is involved in axon guidance 44 and pathogen recognition 45 .
To delineate the gene 'architecture program' of these subsets of DCs, we searched among the 334 fine modules of genes with substantial coexpression and their predicted regulators identified for the entire ImmGen Project compendium (http://www.immgen.org/ModsRegs/ modules.html) to identify those with significant upregulation in specific DC subsets relative to their expression in the rest of the samples from the ImmGen Project (Fig. 3c-e) . Module 150 showed significant upregulation in pDCs (P = 4.77 × 10 -11 ), and predicted regulators of this module included IRF8, STAT2, Runx2 and Egr5 (encoded by Tsc22d1; Fig. 3c ), whose genes were also expressed during the commitment of CDP to pDCs (Fig. 1b and Supplementary Fig. 2) ). Module F156 showed significant upregulation in cDCs (P = 7.01 × 10 -35 ) and significant enrichment for core cDC genes (P = 4.18 × 10 -10 (hypergeometric test)), such as Zbtb46 and Pvrl1. Predicted regulators of this module included BATF3 and RelB (Fig. 3d) , whose genes were also upregulated during the commitment of CDPs to cDCs (Fig. 1b  and Supplementary Fig. 2) ). Module 152 showed significant upregulation in CD8 + cDCs and CD103 + cDCs (P = 1.34 × 10 -25 ) and enrichment for genes of the CD8 + DC and CD103 + DC transcript signature (P < 1 × 10 -13 (hypergeometric test)), such as Tlr3, Xcr1 and Fzd1 (Fig. 3e) . IRF8 and Pbx-1, encoded by genes upregulated in CD8 + cDCs relative to their expression in CD8 -cDCs (Fig. 1b) , were predicted regulators of this module (Fig. 3e) . Module 154 showed significant upregulation in CD8 -cDCs (P = 1.08 × 10 -15 ) and in intestinal CD103 + CD11b + cDCs, a nonlymphoid-tissue cDC subset that has been shown to share development properties with lymphoid-tissue CD8 -cDCs 20 (Supplementary Fig. 5 ). These modules, together with the core gene signature, identified previously unknown genes as well as potential regulators of DC functional specialization in vivo.
CD11b + DC heterogeneity delineates the cDC core gene signature Nonlymphoid-tissue CD11b + cDCs remain the least-wellcharacterized cDC subset both ontogenically and functionally. The small intestine is populated by three phenotypically distinct cDC subsets with different expression of the integrins CD103 and CD11b. CD103 + CD11b -cDCs and CD103 + CD11b + cDCs are derived from CDPs and pre-DCs 46,47 , require Flt3L for their development 47 , migrate efficiently to the draining lymph nodes 48 and are thought to represent cDCs 49 . In contrast, the CD103 -CD11b + subset derives from circulating monocytes 46, 47 , develops independently of Flt3L, requires the ligand for colony-stimulating factor 1 receptor for its development 47 , migrates poorly to the draining lymph nodes 48 and is thought to relate more closely to macrophages than to cDCs 49 .
To determine whether those subsets had differences in their expression of genes of the core cDC signature identified above, we purified CD103 + CD11b -, CD103 + CD11b + and CD103 -CD11b + cDC subsets from the small intestine, as well as CD11b + cDCs from the lung, liver and kidney, and did PCA of those along with the rest of the cDC subsets and with macrophages isolated from the spleen, lung, brain and peritoneum. The CD11b + cDC subsets were distributed across the PCA plot between the cDCs and macrophages (Fig. 4a) and expressed a variable number of cDC core genes (Fig. 4b) , which indicated that nonlymphoid-tissue CD11b + cDCs, as defined at present, represented a heterogenous population.
In the PCA plot, CD103 + CD11b -cDCs from the small intestine clustered with the CD8 + cDCs and CD103 + cDCs, whereas CD103 + CD11b + cDCs from the lamina propria of the small intestine clustered near lymphoid CD8 -cDCs and did not express unique transcripts of CD8 + cDCs and CD103 + cDCs ( Fig. 4a and Supplementary  Fig. 6 ). Accordingly, CD103 + CD11b -cDCs from the small intestine expressed all transcripts specific to the CD8 + cDCs and CD103 + cDCs identified (Fig. 3) , including Fzd1, which encodes a Wnt-receptor signaling molecule (FzD1) that controls activation of β-catenin and its Figs. 4 and 6) . Fzd1 was expressed specifically in CD103 + CD11b -cDCs from the small intestine and was absent from CD103 + CD11b + cDCs and CD103 -CD11b + cDCs from the small intestine (Supplementary Fig. 6 ). Activation of β-catenin and its translocation to the nucleus can control the ability of DCs to promote T cell tolerance in the intestine 50 . Future studies should examine the contribution of FzD1 to the immunomodulatory function of CD103 -CD11b + cDCs in the small intestine. In contrast, the CD103 -CD11b + cDCs clustered near macrophages and away from other DCs in the PCA plot (Fig. 4a) . Consistent with the PCA results, we found that CD103 + CD11b -and CD103 + CD11b + DCs from the small intestine expressed 100% of the core cDC genes and also expressed the cDC-specific proteins c-Kit, Flt3, BTLA and CD26 on the cell surface (Fig. 4b-d and Supplementary Fig. 6 ), which suggested that these two subsets belonged to the lineage. In contrast, CD103 -CD11b + cDCs clustered near macrophages and away from cDCs in the PCA plot (Fig. 4a) , and they expressed only 40% of the cDC genes and lacked the cDC proteins c-Kit, Flt3, BTLA and CD26 on the cell surface (Fig. 4b-d and Supplementary Fig. 6 ), which suggested that the CD103 -CD11b + cDCs from the small intestine belonged to the macrophage lineage. Accordingly, focused analysis of macrophage-associated transcripts indicated that the CD103 -CD11b + cDC population from the small intestine clustered with macrophages (E.L.G. et al., data not shown). Together these results established that the present phenotypic definition of DCs, based on expression of MHC class II and CD11c, is not sufficient to identify tissue DCs and that the use of the cDC gene signature identified here may provide a new means of distinguishing CD11b + cDCs from macrophages in nonlymphoid tissues.
Unique transcriptional signature of migratory DCs
Tissue-draining lymph nodes contain blood-derived DCs that include pDCs, CD8 + cDCs and CD8 -cDCs, also called 'lymph node-resident DCs' , as well as nonlymphoid-tissue CD103 + cDCs and CD11b + cDCs that have migrated from the drained tissue, also called 'tissuemigratory cDCs' 6 . The mechanisms that control the migration and function of nonlymphoid-tissue cDCs in the draining lymph nodes in response to tissue injury or tissue immunization are starting to be Table 1 ; presented as in Fig. 1b) .
(c-e) ImmGen Project fine modules, consisting of genes with high coexpression with projection of module F150 (c), module F156 (d) and module F152 (e) across data from the ImmGen Project (mean of each module). Below, genes expressed in each module, with genes encoding regulators predicted with the Ontogenet algorithm outlined in box (red, predicted activators; blue, predicted repressors). HSC, hematopoietic stem cell; CMP, common myeloid progenitor; CLP, common lympoid progenitor; MEP, megakaryocyte-erythrocyte progenitor; MO, monocyte; preB, pre-B cell; T8 or CD8 T, CD8 + T cell; T4 or CD4 T, CD4 + T cell; GN, granulocyte; B, B cell; NK, natural killer cell. Data are representative of at least three experiments with three or more replicates (unless noted otherwise in Table 1 ).
npg r e s o u r c e elucidated; however, far less is known about the gene program that controls the ability of cDCs to leave peripheral tissues and migrate to the draining lymph nodes or the gene regulators that control the immunological function of migratory cDCs in the uninflamed state 6 . We analyzed the transcriptional program of tissue cDCs before their migration to the draining lymph nodes (parent DC population) and after migration to the lymph nodes, as well as that of lymph noderesident cDCs. Notably, we found that migratory cDCs segregated together in the PCA plot regardless of their cellular or tissue origin, segregated away from the parent cDC populations that populated the drained tissue (Fig. 5a ) and shared a similar transcriptional program (Fig. 5b-e) . Migratory CD11b + cDCs and migratory LCs clustered together with CD103 + migratory cDCs in the PCA plot (Fig. 5a) , which suggested that among tissue CD11b + cDCs, those that migrated in the steady state may have represented the true cDCs. In addition, we found that in contrast to tissue CD11b + cDCs, which had moderate expression of the specific gene Flt3, migratory CD11b + cDCs always had high expression of Flt3. Specifically, epidermal LCs, which develop independently of Flt3 and Flt3L 19 and have very low expression of Flt3 in tissues, showed considerable upregulation of Flt3 once they reached the lymph nodes (Supplementary Fig. 7 ), which suggested a critical role for Flt3 in the homeostasis or function of steady-state migratory cDCs. We also found that tissue-migratory cDCs upregulated some genes encoding molecules dedicated to the dampening of immune responses (Fig. 6 ). As such 'dampening genes' can also be upregulated in response to injury, we further compared steady-state migratory cDCs with poly(I:C)-activated cDCs (Fig. 6a) . As expected, poly(I:C)-activated and steady-state tissue-migratory cDCs upregulated Cd40, which encodes the costimulatory molecule CD40 that has been reported on steady-state migratory LCs 51 (Fig. 6a) ; however, steadystate migratory cDCs did not upregulate genes encoding inflammatory cytokines (Fig. 6b) and had higher expression of genes encoding immunomodulatory molecules than did poly(I:C)-activated cDCs (Fig. 6a) . The genes encoding immunomodulatory molecules that were upregulated in steady-state migratory cDCs included Table 1 ).
npg r e s o u r c e those encoding molecules known to suppress T cell function either directly, such as PD-L1 (encoded by Cd274) 52 , or through the production or activation of immunosuppressive cytokines, such as the TGF-β-activating integrin β 8 (encoded by Itgb8) 53 . Other upregulated genes encoded proteins known to diminish the activation and cytokine production of DCs, including SOCS2, a TLR-responsive molecule that regulates the release of cytokines from DCs via STAT3 modulation 54 ; the inhibitory protein PIAS3 also known to modulate Table 2 ) upregulated at least fivefold in migratory cDCs relative to the mean expression in nonlymphoid-tissue cDCs (red font, transcripts not expressed in nonlymphoid-tissue cDCs, according to the QC95 value). LuLN, lung-draining lymph node. Data are representative of three experiments with three or more replicates (unless noted otherwise in Table 1 ).
npg r e s o u r c e phosphorylation of STAT3 and expression of the transcription factor NF-κB 55 ; and CD200, an immunoregulatory molecule known to diminish the proinflammatory activation of DCs after binding to its receptor, which is also expressed on DCs 56 . Furthermore, steady-state migratory cDCs upregulated genes encoding molecules important in diminishing the survival of DCs, including cell-death receptor Fas (CD95) 57, 58 . By flow cytometry and immunofluorescence analysis, we confirmed expression of Fas, CD200, PD-L1, PIAS3 and CD40 protein in steady-state tissue-migratory cDCs (Fig. 6c,d ). On the basis of these data, we speculate that cDCs that leave nonlymphoid tissues in the steady state upregulate genes that encode components of a transcriptional immunomodulatory program that may prevent the induction of adaptive immune response to self tissue antigens. The functional relevance of the immunomodulatory signature of migratory DCs must be confirmed experimentally.
DISCUSSION
Here we have provided a comprehensive comparative analysis of the transcriptome of DC precursors and tissue DCs across the entire immune system. The results of our study have helped to identify the transcriptional network that accompanies the lineage commitment and diversification of DCs, as well as a DC-specific signature that distinguishes cDCs from macrophages in tissues. They have also elucidated the relationship between lymphoid-tissue and nonlymphoid-tissue DC subsets and predicted regulators of DC diversity, as well as a transcriptional immunomodulatory program expressed specifically during the migration of steady-state tissue DCs to the draining lymph nodes. To gain knowledge of the transcriptional network that controls the commitment of myeloid cells to the DC lineage, we analyzed the transcriptional network associated with three key DC-differentiation checkpoints: common myeloid progenitor to MDP; MDP to CDP; and CDP to either pDC or CD8 + or CD8 -cDC. This analysis identified genes encoding a group of transcriptional activators, including Runx2, Bcl11a and Klf8, whose expression increased specifically during the commitment of MDPs to CDPs but not during their commitment to monocytes, which suggested their potential key role in driving the commitment of myeloid cells to DC-restricted precursors and away from monocytes in vivo. Notably, most of these genes encoded molecules shown to control the pDC lineage, which suggested that differentiation into pDCs represents the 'default' pathway for CDPs. We also characterized the transcriptional networks that accompanied the differentiation of CDPs into pDC, CD8 + cDC and CD8 -cDC subsets and identified several gene candidates whose products may drive DC lineage diversification in vivo.
One of the main controversies in the DC literature is the distinct contribution of cDCs versus macrophages to tissue immunity. This confusion is partly a consequence of the paucity of markers available to distinguish between these two cell types, which has led researchers to use 'promiscuous' markers such as MHC class II, CD11c and F4/80 to assess cDC-or macrophage-specific function 9 . We have identified a core cDC gene signature shared by lymphoid-tissue CD8 -cDCs and CD8 + cDCs and nonlymphoid-tissue CD103 + cDCs and absent from tissue macrophages. The cDC-specific genes included Zbtb46, Flt3, Kit and Ccr7. The identification of Kit as part of the cDC-specific signature was unexpected, as c-Kit and its ligand have never been shown to have an intrinsic role in cDC development in vivo. Additional studies are needed to identify the role, if any, of c-Kit in the differentiation, function and homeostasis of DCs in vivo. Notably, the use of the cDC gene signature helped delineate the heterogeneity of nonlymphoidtissue CD11b + cDCs and identified a contaminating macrophage population that would not have been detected with the phenotypical markers now used to define DC populations in vivo.
We also established that among cDCs, lymphoid-tissue CD8 + cDCs and nonlymphoid-tissue CD103 + cDCs shared a gene signature regardless of the tissue environment in which they resided. The gene signature of CD8 + cDCs and CD103 + cDCs was absent from the rest of the DCs, including Table 1 ).
npg pDCs, CD8 -cDCs and CD103 -cDCs in the same tissues. These results established CD8 + cDCs and CD103 + cDCs as a distinct lineage subset and identified the gene regulators that may drive their differentiation, homeostasis and function. With the algorithm Ontogenet, developed for the data set of the ImmGen Project (V.J. et al., data not shown), we identified modules of genes with substantial coexpression that had specific and different expression in each DC subset. Specifically, we found that modules F150, F156 and F152 were upregulated in pDCs, cDCs and CD8 + cDCs and CD103 + cDCs, respectively, and identified candidate regulatory programs that could be used to predict their expression pattern and therefore may drive the functional specialization of DCs in vivo. Notably, we found that regardless of tissue or cellular origin, nonlymphoid-tissue CD103 + cDCs and CD11b + cDCs as well as epidermal LCs that migrated to the draining lymph nodes in the steady state upregulated a shared gene signature. Some of the genes with the greatest upregulation have been linked to the production of immunosupressive cytokines by DCs, dampening of DC activation and diminished DC survival known to lead to the dampening of T cell activation. These results were consistent with the potential role of steady-state migratory cDCs in the induction or maintenance of the regulatory T cell response 3 and identified candidate molecules that may participate in the control of tolerance to self antigens in vivo.
The results of our study have provided a comprehensive characterization of the transcriptional network of the DC lineage. Our findings should aid in the development of new genetic tools, such as inducible gene regulation in vivo and lineage tracing of genetically marked, defined myeloid precursor populations, to further elucidate the developmental complexity of the phagocyte system. Moreover, the availability of data sets from the ImmGen Project will now permit further investigation into DC gene-expression networks and help delineate the transcriptional program that controls DC function in the steady state and injured state.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: microarray data, GSE15907. data sets. Results of replicates were averaged. The mean expression of each module was projected on the tree.
The Ontogenet algorithm was developed for the data set of the ImmGen Project (V.J. et al., data not shown). This algorithm finds a regulatory program for each coarse and fine module on the basis of regulator expression and the structure of the lineage tree. A one-sided two-sample Kolmogorov-Smirnov test was applied to the mean expression of each fine module of the ImmGen Project for the identification of modules with significantly induced expression in specific cell groups. The cell groups were pDCs, cDCs, CD8 -DCs, CD8 + cDCs and CD103 + cDCs. The background for each was the result obtained for rest of the samples from the ImmGen Project. A Benjamini Hochberg FDR of ≤0.05 was applied to the table of P values of all four groups across all fine modules. A hypergeometric test for two groups was used for estimation of the enrichment of fine modules of the ImmGen Project for the four gene signatures. A Benjamini Hochberg FDR of ≤0.05 was applied to the table of P values of all four groups across all fine modules.
Data analysis and visualization tools. Signature transcripts were clustered and visualized with the HeatMap Viewer or the Hierarchical Clustering tool of the GenePattern genomic analysis platform 62 . For hierarchical clustering, data were log scaled, centered around the mean and clustered with Pearson correlation as a measure and pairwise complete-linkage clustering as a linkage type. Data were centered on rows before visualization. The Immgen PopulationDistances PCA program (http://cbdm.hms.harvard.edu/LabMembersPges/SD.html) was used for PCA. Where indicated, the PCA program was used to identify the 15% of the genes with the greatest difference in expression among subsets by filtering on the basis of a variation of analysis with the geometric standard deviation of populations to 'weight' genes that varied in multiple populations. Data were log-transformed, normalized for gene and subset and filtered for genes with a coefficient of variation of less than 0.5 in each set of sample replicates before visualization. Comparisons of change in expression versus change in expression or of change in expression versus P value (t-test) were visualized with the Multiplot module of GenePattern 62 . Plots of results from individual genes were created with Prism Software.
